Pharmaceutical News

SAN FRANCISCO--(BUSINESS WIRE)--Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development...

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating that Pressure-Enabled...

SAN FRANCISCO--(BUSINESS WIRE)--SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines...

CHICAGO & SAINT GEORGE, Utah--(BUSINESS WIRE)--RxERP and p-Chip Corporation today announced that the companies will jointly present their combined Hardware-Backed Item Identity Solution at GS1 Connect 2026 in Las Vegas on June 10, 2026. The session, "Beyond the Barcode: The Physical-Digital Connection - Linking GS1 Identification to Products," will demonstrate how unit-level digital anchors can be bound to GS1 identifiers and EPCIS events to strengthen pharmaceutical traceability. Serialization...

NEW YORK--(BUSINESS WIRE)--CheckedUp, the leading specialty point of care education platform, today announced it has received accreditation from the Media Rating Council (MRC) for its ad delivery reporting methodology related to TV Video Ad Plays and Explorer Waiting Room TV Engagement across its point of care network. The accreditation follows an audit conducted by an independent CPA firm engaged by MRC and affirms CheckedUp’s adherence to MRC’s rigorous standards for transparency, accuracy, a...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™...

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon receives US FDA approval for expanded indications of TOFIDENCE, a biosimilar to ACTEMRA, in Cytokine Release Syndrome and Pediatric COVID-19....

WAUWATOSA, Wis. & NEWARK, Del.--(BUSINESS WIRE)--N-Zyme Biomedical, a clinical-stage biotechnology company developing a novel class of therapeutics targeting pepsin in reflux disease, today announced the initiation of its Phase 2 clinical trial to evaluate its lead pepsin inhibitor candidate for the treatment of laryngopharyngeal reflux (LPR). The trial represents a key milestone in the development of what is believed to be the first therapeutic approach specifically designed to inhibit pepsin,...

CAMBRIDGE, England--(BUSINESS WIRE)--PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead programme, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. The milestone marks the Company’s progress towards first-in-human clinical trials, with a pipeline of differentiated and first-in-class assets in oncology. PMC-001 is a highly diff...